Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • yvan.wenger
    Member
    • Aug 2009
    • 30

    De-Novo transcriptome with 454 Titanium

    Hello everybody,

    Has somebody done transcriptome assemblies with 454 Titanium sequences?

    The goal of my experiment would be to assemble a comprehensive "transcriptome space" and not to do anything quantitative. Based on preliminary experiments, I expect roughly 15'000-20'000 different genes representing between 25x10⁶ and 50x10⁶ Mb refseq-like transcripts (including all possible exons in each reference sequence).

    I*would particularly be interested if someone could advise/speculate on one or several of these points:

    - PolyA enriched samples vs Normalized samples (loss of rare transcripts? efficiency?)

    - Paired end librairies (overlapping maybe? or particular insert sizes?) vs single end librairies

    - The quantity of reads (or plates assuming 1x10⁶ reads per plate) required to signal a good fraction of all the transcripts expressed (e.g 95-98%)

    - The "average" (for the whole sequencing)*or "minimum" (for rare transcripts) coverage required to obtain a good contiguity after de-novo assembly (e.g. 80%+ full length transcripts)

    - The incidence of the points mentioned above on the presence of rare transcripts such as transcription factors in the final assembly.

    Please don't hesitate to point to recent publications or other threads.

    Cheers,

    Yvan
  • krobison
    Senior Member
    • Nov 2007
    • 734

    #2
    If you search PubMed for "454 AND transcriptome" it gets quite a haul; have you found any of those papers useful or are they too dated (a general problem with this field; the technology evolves faster than people can push publications out!)

    Comment

    • yvan.wenger
      Member
      • Aug 2009
      • 30

      #3
      Yep, most of the publications are focused on "pre-titanium"
      technologies and de-novo transcriptome applications are not so
      common... But I bet that even if the scientific litterature is not so
      prolific at this time, many people are currently working on it.

      Comment

      • flxlex
        Moderator
        • Nov 2008
        • 412

        #4
        Being a bit focused on newbler, I would wait till the new release which includes a transcriptome module for assembly. It generates transcript variants (for example alternative splice variants) grouped according to gene.

        To be fair, there are certainly other programs out there that might do a good, or even better job, for example Abyss: http://www.ncbi.nlm.nih.gov/pubmed/19528083 for Illumina reads (perhaps this works also for 454 reads?).

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 07-20-2026, 11:10 AM
        0 responses
        18 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-13-2026, 10:26 AM
        0 responses
        32 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-09-2026, 10:04 AM
        0 responses
        43 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-08-2026, 10:08 AM
        0 responses
        29 views
        0 reactions
        Last Post SEQadmin2  
        Working...